For minimal residual disease monitoring, that resolution is what determines whether you see a relapse three months before imaging does, or three months after the patient does. For early-stage and paediatric samples, with low tumour burden in low blood volume, it is what determines whether you can run the assay at all.

This is the foundational claim under everything else on the platform. Without it, the rest does not matter.

Send samples to the Simsen lab when you want the turnaround, the accreditation envelope and the interpretation done for you. Bring SiMSen-Seq in-house with LabSuite when you have the bench capacity, want full control of the workflow, or are running volumes that justify an internal pipeline.

Most customers start with one and add the other. Pharma partners often run discovery samples in-house and route confirmatory MRD work to the accredited lab. Translational groups often do the opposite.

.

This is the foundational claim under everything else on the platform. Without it, the rest does not matter.

Personalised ctDNA panels track the variants that matter for the individual patient and the tumour type, and surface resistance markers and clonal evolution over time. The report is built for the people reading it: clinicians, principal investigators, study teams. Each variant has a clinical rationale, not just a score.

If the question is "is there residual disease, yes or no", we will answer it. If the question is "what is the tumour doing now, and what should we change", the platform was built for that one.

For translational research groups and pharma analytics teams, this is non-negotiable. You need to be able to reproduce the call, run a second pipeline against the same data, and publish without a vendor sitting between you and the result. We work that way by default.

It also means we get told when our pipeline is wrong. We prefer that to the alternative.

Co-authorship on the resulting paper, where the science supports it. Protocol design help up front, when an early conversation can save a sample run later. Interpretation help when a result is unusual and you want a second set of eyes on it.

We are not the right partner for every project. We are an exceptionally good partner for the ones we are right for.